Studies Advance Lexaria Bioscience Technology to Improve Pharmaceutical Drugs

0

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.

  • Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to improve their performance and accelerate their rate of effective utilization.
  • The company’s flagship product, DehydraTECH(MT) has had many successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and viral infections.
  • More recently, the company reported successes in increasing the speed and effectiveness of a drug to treat erectile dysfunction (“ED”) in laboratory animals.
  • Lexaria is preparing an Investigational New Drug (“IND”) application for its hypertension study line to seek FDA New Drug Application (“NDA”) approval

The recent announcement that patented DehydraTECH(TM) technology from drug bio-efficacy innovator Lexaria Bioscience (NASDAQ: LEXX) may be useful in the treatment of erectile dysfunction by improving the speed of drug efficacy Sildenafil (common as Viagra) follows a number of development successes reported by Lexaria.

DehydraTECH is a proprietary technology that changes the way the body detects and absorbs drugs by combining Active Pharmaceutical Ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of particle carrier, synthesizing it through a dehydration procedure and making it the resulting powder or liquid as a final product capable of being rapidly absorbed by…

Learn more>>

About InvestorWire

InvestorWire is the transfer service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wired broadcast products you’ll need to ensure your next press release grabs your target audience’s attention and stays with you. While our competitors come at you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all national versions. While other delivery services can provide a basic review of your release, InvestorWire helps you put your best foot forward with Improved press release.

With our competitors, the job is done the second your version crosses the line. Not with InvestorWire. We include follow-up coverage of each release taking advantage of the ever-growing audiences of the 50+ brands who make up the InvestorBrandNetwork.

Get the most out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or republished: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Image from Pixabay

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.

This article was submitted by an external contributor and may not represent the views and opinions of Benzinga.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Share.

Comments are closed.